DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Oxbryta is a drug marketed by Global Blood Theraps and is included in one NDA. There are nine patents protecting this drug.
This drug has two hundred and eighteen patent family members in thirty-four countries.
The generic ingredient in OXBRYTA is voxelotor. Additional details are available on the voxelotor profile page.
Oxbryta will be eligible for patent challenges on November 25, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 12, 2037. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for OXBRYTA
DrugPatentWatch® Estimated Generic Entry Opportunity Date for OXBRYTA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OXBRYTA
Identify potential brand extensions & 505(b)(2) entrants
|Emory University||Phase 2|
|Global Blood Therapeutics||Phase 2|
|Global Blood Therapeutics||Phase 4|
|Country||Patent Number||Estimated Expiration|
|Chile||2015002567||⤷ Free Forever Trial|
|Argentina||095342||⤷ Free Forever Trial|
|Taiwan||I695830||⤷ Free Forever Trial|
|European Patent Office||3141542||⤷ Free Forever Trial|
|Brazil||112014016165||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|